Fifteen Years' Experience of the Brazilian Osteosarcoma Treatment Group (BOTG): A Contribution from an Emerging Country
Carregando...
Citações na Scopus
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
MARY ANN LIEBERT, INC
Autores
PETRILLI, Antonio Sergio
BRUNETTO, Algemir Lunardi
CYPRIANO, Monica dos Santos
MACEDO, Carla Renata Pacheco Donato
SENERCHIA, Andreza Almeida
COSTA, Cecilia Maria da
LUSTOSA, Daniel
BORSATO, Maria Luiza
Citação
JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, v.2, n.4, p.145-152, 2013
Resumo
Purpose: Little information is available regarding the tumor features, prognostic factors, and treatment results in children and adolescents and young adults (AYAs) with osteosarcoma diagnosed in developing countries. We reviewed the results of three observational cohorts of osteosarcoma patients treated in an emerging country. Methods: A total of 604 patients below the age of 30 years with high-grade osteosarcoma were prospectively enrolled in the Brazilian Osteosarcoma Treatment Group (BOTG) studies III, IV, and V. Gender, age, time from onset of symptoms to diagnosis, primary tumor site, presence or absence of metastases at diagnosis, tumor size, type of surgery (limb-sparing or amputation), treatment protocol, and histological response were correlated with survival. Results: The estimated 5-year overall survival and event-free survival (EFS) rates for the 553 eligible patients were 49% and 39% respectively; of the 390 non-metastatic patients included in the total, overall-and event-free survival were 59% and 48% respectively. Metastases at diagnosis, primary tumor site, type of surgery, and histological response were significant predictors of overall survival and EFS in univariate and multivariate analysis, whereas tumor size and treatment protocol lost prognostic significance in multivariate analysis. Conclusion: We report on the outcome of three consecutive studies for the treatment of osteosarcoma carried out in Brazil over 15 years. Although the survival rates presented are below those reported in current literature, it represents the result of a favorable experience gathered from the national collaborative work.
Palavras-chave
osteosarcoma, survival, prognostic factors, emerging country, cooperative group
Referências
- Andreou D, 2011, ANN ONCOL, V22, P1228, DOI 10.1093/annonc/mdq589
- Bacci G, 2006, CANCER, V106, P1154, DOI 10.1002/cncr.21724
- Bacci G, 2001, EUR J SURG ONCOL, V27, P98, DOI 10.1053/ejso.2000.1056
- Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
- Chou AJ, 2009, CANCER, V115, P5339, DOI 10.1002/cncr.24566
- Eselgrim M, 2006, PEDIATR BLOOD CANCER, V47, P42, DOI 10.1002/pbc.20608
- Ferrari S, 2005, J CLIN ONCOL, V23, P8845, DOI 10.1200/JCO.2004.00.5785
- Huvos AG, 1990, BONE TUMORS DIAGNOSI
- Instituto Brasileiro de Geografia e Estatistica, 2010, CENS 2010
- Instituto Brasileiro de Geografia e Estatistica-IBGE Ministerio do Planejamento Orcamento e Gestao, 2008, PROJ POP BRAS SEX ID
- Jaffe N, 2009, CANC TREAT, V152, P239, DOI 10.1007/978-1-4419-0284-9_12
- Jaffe N, 1993, Cancer Treat Res, V62, P75
- Jaffe N, 2005, CLIN ORTHOP RELAT R, P19, DOI 10.1097/01.blo.0000180509.90557.43
- JAFFE N, 1983, CANCER, V51, P402, DOI 10.1002/1097-0142(19830201)51:3<402::AID-CNCR2820510308>3.0.CO;2-P
- JAFFE N, 1991, CLIN ORTHOP RELAT R, P15
- Lewis IJ, 2007, J NATL CANCER I, V99, P112, DOI 10.1093/inci/djk015
- Meyers PA, 2005, J CLIN ONCOL, V23, P2004, DOI 10.1200/JCO.2005.06.031
- Mirabello L, 2009, CANCER, V115, P1531, DOI 10.1002/cncr.24121
- Petrilli AS, 1999, MED PEDIATR ONCOL, V33, P71, DOI 10.1002/(SICI)1096-911X(199908)33:2<71::AID-MPO2>3.0.CO;2-T
- Petrilli AS, 2006, J CLIN ONCOL, V24, P1161, DOI 10.1200/JCO.2005.03.5352
- PETRILLI AS, 1991, CANCER, V68, P733, DOI 10.1002/1097-0142(19910815)68:4<733::AID-CNCR2820680412>3.0.CO;2-0
- PETRILLI S, 1991, CLIN ORTHOP RELAT R, P60
- Ribeiro RC, 2005, NEW ENGL J MED, V352, P2158, DOI 10.1056/NEJMp048313
- Seibel NL, 2007, CANCER, V109, P1646, DOI 10.1002/cncr.22553
- Smith MA, 2010, J CLIN ONCOL, V28, P2625, DOI 10.1200/JCO.2009.27.0421